{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:28:43Z","timestamp":1783031323975,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1023\/b:brea.0000004371.48757.19","type":"journal-article","created":{"date-parts":[[2003,11,19]],"date-time":"2003-11-19T14:31:53Z","timestamp":1069252313000},"page":"155-164","source":"Crossref","is-referenced-by-count":73,"title":["Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2\/HER2"],"prefix":"10.1007","volume":"82","author":[{"given":"Marc","family":"Azemar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirus","family":"Djahansouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Solbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Mross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter von","family":"Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Groner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried S.","family":"Wels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5151826_CR1","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"MA Olayioye","year":"2000","unstructured":"Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000","journal-title":"EMBO J"},{"key":"5151826_CR2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5151826_CR3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW, Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760, 2003","journal-title":"Nature"},{"key":"5151826_CR4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","volume":"11","author":"TP Garrett","year":"2003","unstructured":"Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11: 495-505, 2003","journal-title":"Mol Cell"},{"key":"5151826_CR5","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","volume":"19","author":"J Mendelsohn","year":"2000","unstructured":"Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000","journal-title":"Oncogene"},{"key":"5151826_CR6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002","journal-title":"J Clin Oncol"},{"key":"5151826_CR7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001","journal-title":"N Engl J Med"},{"key":"5151826_CR8","first-page":"44","volume":"5","author":"RJ Kreitman","year":"2003","unstructured":"Kreitman RJ: Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 5: 44-51, 2003","journal-title":"Curr Opin Mol Ther"},{"key":"5151826_CR9","first-page":"6310","volume":"52","author":"W Wels","year":"1992","unstructured":"Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE: Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52: 6310-6317, 1992","journal-title":"Cancer Res"},{"key":"5151826_CR10","doi-asserted-by":"crossref","first-page":"15160","DOI":"10.1016\/S0021-9258(18)42160-6","volume":"267","author":"IM Harwerth","year":"1992","unstructured":"Harwerth IM, Wels W, Marte BM, Hynes NE: Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267: 15160-15167, 1992","journal-title":"J Biol Chem"},{"key":"5151826_CR11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/iai.15.1.138-144.1977","volume":"15","author":"BH Iglewski","year":"1977","unstructured":"Iglewski BH, Liu PV, Kabat D: Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphateribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect Immun 15: 138-144, 1977","journal-title":"Infect Immun"},{"key":"5151826_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I","volume":"87","author":"A Keppler-Hafkemeyer","year":"2000","unstructured":"Keppler-Hafkemeyer A, Kreitman RJ, Pastan I: Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 87: 86-94, 2000","journal-title":"Int J Cancer"},{"key":"5151826_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/gyno.2000.6040","volume":"80","author":"M Schmidt","year":"2001","unstructured":"Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC: Synergistic interaction between an anti-p185HER-2 Pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80: 145-155, 2001","journal-title":"Gynecol Oncol"},{"key":"5151826_CR14","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V91.5.1820","volume":"91","author":"A Spyridonidis","year":"1998","unstructured":"Spyridonidis A, Schmidt M, Bernhardt W, Papadimitriou A, Azemar M, Wels W, Groner B, Henschler R: Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood 91: 1820-1827, 1998","journal-title":"Blood"},{"key":"5151826_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ijc.2910600120","volume":"60","author":"W Wels","year":"1995","unstructured":"Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE: EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer 60: 137-144, 1995","journal-title":"Int J Cancer"},{"key":"5151826_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO;2-8","volume":"86","author":"M Azemar","year":"2000","unstructured":"Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86: 269-275, 2000","journal-title":"Int J Cancer"},{"key":"5151826_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pros.1043","volume":"47","author":"L Wang","year":"2001","unstructured":"Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan Z: Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 47: 21-28, 2001","journal-title":"Prostate"},{"key":"5151826_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0378-1119(94)00786-R","volume":"159","author":"W Wels","year":"1995","unstructured":"Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE, Groner B: Biotechnological and gene therapeutic strategies in cancer Treatment. Gene 159: 73-80, 1995","journal-title":"Gene"},{"key":"5151826_CR19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D","volume":"73","author":"U Altenschmidt","year":"1997","unstructured":"Altenschmidt U, Schmidt M, Groner B, Wels W: Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin. Int J Cancer 73: 117-124, 1997","journal-title":"Int J Cancer"},{"key":"5151826_CR20","first-page":"2661","volume":"58","author":"M Maurer-Gebhard","year":"1998","unstructured":"Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stocklin E, Wels W, Groner B: Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 58: 2661-2666, 1998","journal-title":"Cancer Res"},{"key":"5151826_CR21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","volume":"18","author":"RJ Kreitman","year":"2000","unstructured":"Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622-1636, 2000","journal-title":"J Clin Oncol"},{"key":"5151826_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","volume":"345","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247, 2001","journal-title":"N Engl J Med"},{"key":"5151826_CR23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nm0396-350","volume":"2","author":"LH Pai","year":"1996","unstructured":"Pai LH, Wittes R, Setser A, Willingham MC, Pastan I: Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 2: 350-353, 1996","journal-title":"Nat Med"},{"key":"5151826_CR24","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990","journal-title":"Oncogene"},{"key":"5151826_CR25","first-page":"165","volume":"1198","author":"NE Hynes","year":"1994","unstructured":"Hynes NE, Stern DF: The biology of erbB-2\/neu\/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994","journal-title":"Biochim Biophys Acta"},{"key":"5151826_CR26","doi-asserted-by":"crossref","first-page":"18327","DOI":"10.1016\/S0021-9258(17)32310-4","volume":"269","author":"Y Reiter","year":"1994","unstructured":"Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 269: 18327-18331, 1994","journal-title":"J Biol Chem"},{"key":"5151826_CR27","first-page":"2311","volume":"5","author":"LH Pai-Scherf","year":"1999","unstructured":"Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I: Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 5: 2311-2315, 1999","journal-title":"Clin Cancer Res"},{"key":"5151826_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/scbi.1996.0012","volume":"7","author":"CR King","year":"1996","unstructured":"King CR, Fischer PH, Rando RF, Pastan I: The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. Semin Cancer Biol 7: 79-86, 1996","journal-title":"Semin Cancer Biol"},{"key":"5151826_CR29","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1073\/pnas.140210597","volume":"97","author":"Y Tsutsumi","year":"2000","unstructured":"Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I: Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97: 8548-8553, 2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"5151826_CR30","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.4049\/jimmunol.165.12.7150","volume":"165","author":"M Onda","year":"2000","unstructured":"Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I: Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J Immunol 165: 7150-7156, 2000","journal-title":"J Immunol"},{"key":"5151826_CR31","first-page":"5070","volume":"61","author":"M Onda","year":"2001","unstructured":"Onda M, Nagata S, Tsutsumi Y, Vincent JJ, Wang Q, Kreitman RJ, Lee B, Pastan I: Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 61: 5070-5077, 2001","journal-title":"Cancer Res"},{"key":"5151826_CR32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s002620100226","volume":"50","author":"YL Yip","year":"2002","unstructured":"Yip YL, Ward RL: Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 50: 569-587, 2002","journal-title":"Cancer Immunol Immunother"},{"key":"5151826_CR33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 95: 1592-1600, 2002","journal-title":"Cancer"},{"key":"5151826_CR34","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.4049\/jimmunol.158.10.4584","volume":"158","author":"B Gerstmayer","year":"1997","unstructured":"Gerstmayer B, Altenschmidt U, Hoffmann M, Wels W: Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J Immunol 158: 4584-4590, 1997","journal-title":"J Immunol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:BREA.0000004371.48757.19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:BREA.0000004371.48757.19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/B:BREA.0000004371.48757.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:BREA.0000004371.48757.19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:35:48Z","timestamp":1750894548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:BREA.0000004371.48757.19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["5151826"],"URL":"https:\/\/doi.org\/10.1023\/b:brea.0000004371.48757.19","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}